Atriva Therapeutics announces changes in its Management Team

• Prof. Oliver Planz to step down as CSO at Atriva by mid-year 2022
• Prof. Planz will continue to serve Atriva as Chairman of the Scientific Advisory Board

Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, announced today that Prof. Dr. Oliver Planz will not extend his contract as Chief Scientific Officer (CSO) beyond June 30, 2022. The Atriva co-founder and co-inventor of its technology will continue to serve the company in an advisory capacity as Chairman of the Scientific Advisory Board and will further expand the Scientific Advisory Board.

Prof. Dr. Oliver Planz has served as executive advisor and CSO with Atriva Therapeutics since 2015 when the company was founded. He will continue as Head of the Research Group “Translational Immunology of Infection”, Department of Immunology at the Interfaculty Institute for Cell Biology at the Eberhard-Karls-University of Tübingen.

“On behalf of the Advisory Board and the company, I would like to thank Oliver Planz for his great commitment and constant dedication to Atriva. We greatly respect and appreciate the scientific successes and milestones Atriva has achieved to date under Oliver’s scientific leadership and look forward to a continued fruitful collaboration,” said Dr. Ulrich Dauer, Chairman of the Atriva Therapeutics Advisory Board.

“I also sincerely thank Oliver Planz for his contribution to Atriva Therapeutics. He was fully instrumental in bringing the company to where we stand today. We have already taken steps to hire a new, full-time CSO for Atriva. With the transition into late-stage clinical development as well as an expansion of the indications under investigation, Atriva is currently making vital decisions to set the right course for the future and to exploit all opportunities”, commented Dr. Rainer Lichtenberger, CEO of Atriva Therapeutics.

The preclinical work for Atriva in the Tübingen laboratories will continue under the leadership of Prof. Planz, at least through the end of 2022. Corresponding agreements have already been concluded with all parties involved.